The stock of Nexalin Technology Inc (NASDAQ:NXL) last traded at $3.16, unchanged from the previous session.
NXL stock price is now -9.74% away from the 50-day moving average and 73.30% away from the 200-day moving average. The market capitalization of the company currently stands at $42.04M.
In other news, Owens David, Chief Medical Officer bought 500 shares of the company’s stock on Oct 28 ’24. The stock was bought for $1,095 at an average price of $2.19. Upon completion of the transaction, the Chief Medical Officer now directly owns 148,293 shares in the company, valued at $0.47 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 13 ’24, Chief Medical Officer Owens David bought 1,000 shares of the business’s stock. A total of $950 was incurred on buying the stock at an average price of $0.95. This leaves the insider owning 147,793 shares of the company worth $0.47 million. A total of 18.79% of the company’s stock is owned by insiders.
During the past 12 months, Nexalin Technology Inc has had a low of $0.25 and a high of $4.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 16.39, and a quick ratio of 15.86. The fifty day moving average price for NXL is $3.5011 and a two-hundred day moving average price translates $1.823415 for the stock.
The latest earnings results from Nexalin Technology Inc (NASDAQ: NXL) was released for 2024-06-30. The net profit margin was -3427.10% and return on equity was -135.57% for NXL. The company reported revenue of $36000.0 for the quarter, compared to $24000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 50.0 percent. For the current quarter, analysts expect NXL to generate $30k in revenue.
